Volume | 1,850,547 |
|
|||||
News | - | ||||||
Day High | 331.78 | Low High |
|||||
Day Low | 325.82 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
329.23 | 325.82 | 331.78 | 329.99 | 332.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
38,453 | 1,850,547 | $ 329.48 | $ 609,716,134 | - | 243.17 - 354.46 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:05 | 2 | $ 333.87 | USD |
Vertex Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 85.00B | 257.59M | 256.51M | $ 2.37B | $ 6.89M | 2.72 | 12,342.52 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 108.20k | 0.20% |
Vertex Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 341.37 | 345.805 | 325.82 | 335.77 | 1,160,606 | -11.38 | -3.33% |
1 Month | 338.50 | 354.46 | 325.82 | 342.79 | 1,092,644 | -8.51 | -2.51% |
3 Months | 290.52 | 354.46 | 283.60 | 321.71 | 1,084,692 | 39.47 | 13.59% |
6 Months | 313.78 | 354.46 | 282.21 | 311.30 | 1,245,410 | 16.21 | 5.17% |
1 Year | 270.84 | 354.46 | 243.17 | 299.16 | 1,357,743 | 59.15 | 21.84% |
3 Years | 288.00 | 354.46 | 176.36 | 245.28 | 1,685,661 | 41.99 | 14.58% |
5 Years | 156.60 | 354.46 | 144.07 | 227.82 | 1,566,968 | 173.39 | 110.72% |
Vertex Pharmaceuticals Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |